Abstract 1949P
Background
Conventional use of doxorubicin as a single-agent or in combinations with other drugs in the treatment of uterine sarcomas is associated with dose-limiting toxicities. Doxorubicin plus trabectedin was shown to increase progression-free survival (PFS) at the price of higher toxicity. PLD plus trabectedin revealed to be feasible in larger phase 2 and 3 randomised studies in ovarian cancer. We hypothesise that the therapeutic index of trabectedin plus PLD could be superior to the combination with doxorubicin because of a more favourable toxicity profile.
Methods
In this retrospective single-arm study the clinical outcome was analysed in 21 patients with uterine sarcomas treated with PLD 30 mg/m2 plus trabectedin 1.1 mg/m2 every three weeks between January 2000 and April 2023 at the University Hospital in Innsbruck. Response evaluation was done every 3 cycles and every 3 months during the post-treatment follow-up. Toxicity was evaluated according to the National Cancer Institute-Common Terminology criteria, on a total of 148 administered cycles in 33 patients.
Results
In 66% of patients PLD plus trabectedin was given as first-line treatment, in 19% and 14% as second and third-line treatment, respectively. After 6 months one patient (4.8%) achieved complete remission (CR), four others (19%) showed a partial remission (PR), resulting in an objective response rate (ORR) of 24%. Four patients (19%) showing stable disease (SD), resulting in a clinical benefit rate (= ORR + SD) of 43%; progression was recorded in 12 patients (57%). Median PFS was 6.0 months (SD: ±21 months), while median overall survival was 26 months (SD: ±32 months). A median of 4 (range: 1-11) cycles per patient were given. Regarding ≥ grade 3 toxicity, thrombocytopenia was recorded in 9%, anaemia in 12% and neutropenia in 36% of patients. Febrile neutropenia was present in 7 patients (21%). Haematologic toxicity was the most frequent reason for dose delays (25 events) and dose reductions in eight cases.
Conclusions
Compared to conventional doxorubicin plus trabectedin, the herein investigated combination shows limited but similar anti-tumor efficacy in metastatic uterine sarcomas, but exhibits a more favourable toxicity profile.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1960P - Clinical outcomes of the patients with alveolar soft part sarcoma developed brain metastasis
Presenter: Yu Toda
Session: Poster session 15
1961P - Prevalence of diagnostic discrepancies in soft tissue and bone tumors from initial diagnosis to referral center
Presenter: Khomsit Thongthammachat
Session: Poster session 15
1963P - Comprehensive profiling of chordoma reveals tumor microenvironment subtypes and unique molecular findings
Presenter: Marina Voropaeva
Session: Poster session 15
1964P - Biomimetics of three-dimensional (3D) osteosarcoma (OS) models: A scoping review
Presenter: Vinesh Sandhu
Session: Poster session 15
1965P - Transcriptional analysis of immune microenvironment of chordomas of the skull base and mobile spine
Presenter: Jason Roszik
Session: Poster session 15
1966P - Extending the interval of denosumab treatment for unresectable giant cell tumor of bone
Presenter: Toshiyuki Kunisada
Session: Poster session 15
1967P - A single-arm multicenter trial of the combination of anlotinib with chemotherapy in patients with stage IIb classic osteosarcoma of the extremity
Presenter: Fan Tang
Session: Poster session 15
1968P - Metastatic Ewing sarcoma, patterns of care and outcomes of patients in a real-life setting: The Metabone national observational study
Presenter: coline ducrot
Session: Poster session 15
1969P - Intratumoral immune infiltrates in chondrosarcoma (ChS)
Presenter: Piotr Rutkowski
Session: Poster session 15
1970P - Metastatic chondrosarcoma, patterns of care and outcomes of patients in a real-life setting: The Metabone national observational study
Presenter: coline ducrot
Session: Poster session 15